Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Laboratorio Reig Jofre Company

RJF.MC
ES0165359029
A140EW

Price

3.01
Today +/-
+0.09
Today %
+3.04 %
P

Laboratorio Reig Jofre stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Laboratorio Reig Jofre stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Laboratorio Reig Jofre stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Laboratorio Reig Jofre stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Laboratorio Reig Jofre's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Laboratorio Reig Jofre Stock Price History

DateLaboratorio Reig Jofre Price
10/11/20243.01 undefined
10/10/20242.92 undefined
10/9/20242.93 undefined
10/8/20242.80 undefined
10/7/20242.78 undefined
10/4/20242.75 undefined
10/3/20242.80 undefined
10/2/20242.78 undefined
10/1/20242.78 undefined
9/30/20242.75 undefined
9/27/20242.74 undefined
9/26/20242.75 undefined
9/25/20242.74 undefined
9/24/20242.75 undefined
9/23/20242.76 undefined
9/20/20242.78 undefined
9/19/20242.73 undefined
9/18/20242.71 undefined
9/17/20242.73 undefined
9/16/20242.71 undefined

Laboratorio Reig Jofre Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Laboratorio Reig Jofre, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Laboratorio Reig Jofre from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Laboratorio Reig Jofre’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Laboratorio Reig Jofre. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Laboratorio Reig Jofre’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Laboratorio Reig Jofre’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Laboratorio Reig Jofre’s growth potential.

Laboratorio Reig Jofre Revenue, EBIT and net profit per share

DateLaboratorio Reig Jofre RevenueLaboratorio Reig Jofre EBITLaboratorio Reig Jofre Net Income
2026e404.69 M undefined20.91 M undefined18.19 M undefined
2025e377.68 M undefined17.93 M undefined15.77 M undefined
2024e350.29 M undefined14.44 M undefined13.22 M undefined
2023316.09 M undefined12.23 M undefined9.41 M undefined
2022271.15 M undefined9.51 M undefined8.11 M undefined
2021236.23 M undefined9.3 M undefined5.09 M undefined
2020230.08 M undefined9.59 M undefined5.67 M undefined
2019200.21 M undefined6.57 M undefined4.94 M undefined
2018180.47 M undefined8.83 M undefined9.27 M undefined
2017167.98 M undefined9.02 M undefined8.83 M undefined
2016161.13 M undefined9.78 M undefined7.68 M undefined
2015156.91 M undefined11.75 M undefined8.75 M undefined
201433.28 M undefined2.8 M undefined2.31 M undefined
2013121.7 M undefined15.6 M undefined9.5 M undefined
201231.4 M undefined2 M undefined1 M undefined
201129.9 M undefined100,000 undefined0 undefined
201029.5 M undefined-5.4 M undefined16.1 M undefined
200939 M undefined-7.7 M undefined-22.6 M undefined
2008135.5 M undefined-14.8 M undefined-44.9 M undefined
2007161.8 M undefined13.4 M undefined1.5 M undefined
2006154.1 M undefined13.2 M undefined3.8 M undefined
200594.5 M undefined4.8 M undefined4.6 M undefined
200449.4 M undefined1.8 M undefined3.8 M undefined

Laboratorio Reig Jofre Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
131313192349941541611353929293112133156161167180200230236271316350377404
---46.1521.05113.0491.8463.834.55-16.15-71.11-25.64-6.90290.32-72.73372.733.213.737.7811.1115.002.6114.8316.6110.767.717.16
23.087.6938.4642.1143.4846.9450.0059.0959.6351.1174.3672.4175.8674.1961.9857.5862.1862.1164.0765.0065.5062.6162.7159.4158.23---
315810234791966929212223751997100107117131144148161184000
0-2112141313-14-7-50215211998699912141720
--15.387.695.268.702.044.268.448.07-10.37-17.95-17.24-6.4512.406.067.055.595.394.443.003.913.813.323.804.004.514.95
0-30233431-44-22160192878945589131518
----50.00-33.33-25.00-66.67-4,500.00-50.00-172.73--800.00-77.78300.00-12.5014.2912.50-55.5625.00-60.0012.5044.4415.3820.00
----------------------------
----------------------------
0.10.110.310.313.111.415.117.117.117.217.317.317.317.567.366.0866.7567.8367.0369.4373.579.2179.0878.978.8000
----------------------------
Details

Keystats

Revenue and Growth

The Laboratorio Reig Jofre Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Laboratorio Reig Jofre is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19992000200120022003200420052006200720082009201020112012201320132014201520162017201820192020202120222023
                                                   
0.200.91.99.34.81731.6381.32.383.517.65.49.45.412.6911.8219.3314.9610.9611.112.396.046.96.49
1.61.62.13.36.913.728.134.637.218.676.14.53.819.33.829.8134.2535.9935.1633.8640.5442.6244.4249.3355.81
000.30.301.65.12.53.51.93.21.510.810.81.020.070.0602.134.144.626.025.596.05
7.24.85.87.19.832.334.540.3364.65.22.32.82.621.32.623.8424.8933.0127.5134.5638.3540.4547.6848.1961.86
00000.1000000090.830.84.993.986.643.610.362.290.654.682.32.34
96.49.112.626.152.484.7109114.726.417.793.434.913.45413.472.3575.0195.0281.2481.8696.42100.73108.84112.3132.55
7.37.71316.316.644.344.647.338.64.40.60.30.30.223.10.224.0528.6536.5446.7554.7383.9285.2892.3993.1991.63
0.50.71.10.12.12.917.98.410.353.382.30.70.18.61.38.69.969.090.590.720.731.882.252.365.156.39
000000000000000000000006.165.610
0.50.811.82.92.53.25.961.71.10.70.50.52.10.532.4532.6132.1932.5239.1285.8882.8377.7370.8963.07
005.34.94.450.1130.5133.8124.110370.25959596.85925.4125.1727.9527.7427.629.7329.9729.8428.9727.99
000.70.50.74.28.113.113.711.211.211.23.220216.5316.5413.0114.3715.6415.7916.0913.8210.688.93
8.39.221.123.626.7104204.3208.5192.7173.6165.471.963.170.333.370.3108.4112.04110.27122.1137.82217.19216.42222.3214.5198
17.315.630.236.252.8156.4289317.5307.4200183.1165.39883.787.383.7180.74187.05205.29203.34219.68313.62317.15331.14326.8330.55
                                                   
2.77.214.614.618.524.732.932.932.932.932.932.932.932.9332.9126.43126.4331.6132.0832.5338.0338.438.7239.2139.82
000016.250.1103.5103.5103.5103.5103.5103.5103.5103.50103.5000001919191919
1.7-2.1-1.80.23.36.816.415.916-37.8-63-49.8-49.6-60.740.5-60.7-4.484.22103.47111.01119.45123.5129.18133.91141.55150.31
00-0.3-0.6-0.81.31.3-2.3-12.8-0.100001.201.10.450.29-0.78-1.27-1.19-0.32-0.63-2.31-1.95
00000000000000000000000000
4.45.112.514.237.282.9154.1150139.698.573.486.686.875.744.775.7123.05131.09135.36142.31150.7179.34186.25191197.45207.18
1.31.81.922.613.825.232.226.114.213.49.76.53.815.13.824.823.2722.1319.7724.7831.1432.9835.0736.141.48
000000002.4100.71.30.73.90.70.73.773.664.214.574.687.146.317.147.41
0.20.30.61.93.62.77.612.72215.84.32.81.513.815.046.214.984.414.5118.6523.4615.218.5311.21
10.86.26.865.112.318.239.636.829.461.7003.4010.186.7212.694.733.656.520000
00000000.19.634.477.8451.51.60.61.60.60.590.591.351.547.5814.2318.3323.8330.09
12.38.39.39.911.328.85184.696.994.8101.559.910.87.126.87.141.3140.5544.0634.4739.0568.5777.8174.9175.690.19
0.72.15.59.51.240.470.174.662.16.70.210.1009.9012.2110.3517.2317.0921.0642.542.7949.0637.4123.4
000005.27.26.660.600.500204.833.773.353.293.243.13.323.052.82.63
00.232.73.12.712.910.910.54.58.18.20.514.114.216.217.46.936.5921.318.759.4410.8310.08
0.72.38.512.24.348.390.292.178.611.88.318.80.5116121.2620.3327.9827.3130.8966.9154.8661.5551.0436.11
1310.617.822.115.677.1141.2176.7175.5106.6109.878.711.38.142.88.162.5760.8872.0461.7869.94135.48132.67136.46126.64126.29
17.415.730.336.352.8160295.3326.7315.1205.1183.2165.398.183.887.583.8185.62191.97207.4204.09220.63314.82318.93327.46324.09333.48
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Laboratorio Reig Jofre provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Laboratorio Reig Jofre's financial health and stability.

Assets

Laboratorio Reig Jofre's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Laboratorio Reig Jofre must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Laboratorio Reig Jofre after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Laboratorio Reig Jofre's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132013null2014201520162017201820192020202120222023
40134-43-1916-12112112111189565810
1255761100404055671316182123
00000000000000000000000
-5-1402110-201-2-6-2-4-2-4-6-4-176-2-8-5-8-5-14
-1011-43412-221010100-100140-80
00000815401010110010011
00000000002020011111001
-1-1063117-23-5-7-5012012-312-120141122141619
-5-29-8-12-8-60000-50-5-7-10-12-17-21-31-15-19-11-12
-3-74-94-9-130317014-514-5-5-9-13-9-20-50-30-34-12-12
1-45-852690327114014021-180-19-14-14-10
00000000000000000000000
-743311-11-149-25-630-40-49-214-731767-3-7
203665-201000000000000231000
128096-5-11-136-25-63-12-5-12-58-213-7240913-2-7
000-400-20000000000001610
000000000-120-1200000000000
7-49164-33001222201-13-311-610
-6.95-39.32-1.9818.99.6-29.6-6.01-7.75-6.38-0.087.02-0.080-10.792.4-13.733.13-6.31-19.476.55-5.274.756.35
00000000000000000000000

Laboratorio Reig Jofre stock margins

The Laboratorio Reig Jofre margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Laboratorio Reig Jofre. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Laboratorio Reig Jofre.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Laboratorio Reig Jofre's sales revenue. A higher gross margin percentage indicates that the Laboratorio Reig Jofre retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Laboratorio Reig Jofre's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Laboratorio Reig Jofre's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Laboratorio Reig Jofre's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Laboratorio Reig Jofre. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Laboratorio Reig Jofre's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Laboratorio Reig Jofre Margin History

Laboratorio Reig Jofre Gross marginLaboratorio Reig Jofre Profit marginLaboratorio Reig Jofre EBIT marginLaboratorio Reig Jofre Profit margin
2026e58.28 %5.17 %4.5 %
2025e58.28 %4.75 %4.17 %
2024e58.28 %4.12 %3.77 %
202358.28 %3.87 %2.98 %
202259.42 %3.51 %2.99 %
202162.81 %3.94 %2.16 %
202062.59 %4.17 %2.47 %
201965.89 %3.28 %2.47 %
201865.2 %4.89 %5.13 %
201764.08 %5.37 %5.26 %
201662.13 %6.07 %4.76 %
201562.31 %7.49 %5.58 %
201459.7 %8.4 %6.94 %
201361.96 %12.82 %7.81 %
201273.89 %6.37 %3.18 %
201173.58 %0.33 %0 %
201073.56 %-18.31 %54.58 %
200975.38 %-19.74 %-57.95 %
200850.92 %-10.92 %-33.14 %
200759.58 %8.28 %0.93 %
200659.31 %8.57 %2.47 %
200550.69 %5.08 %4.87 %
200447.17 %3.64 %7.69 %

Laboratorio Reig Jofre Stock Sales Revenue, EBIT, Earnings per Share

The Laboratorio Reig Jofre earnings per share therefore indicates how much revenue Laboratorio Reig Jofre has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Laboratorio Reig Jofre earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Laboratorio Reig Jofre's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Laboratorio Reig Jofre’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Laboratorio Reig Jofre's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Laboratorio Reig Jofre Revenue, EBIT and net profit per share

DateLaboratorio Reig Jofre Sales per ShareLaboratorio Reig Jofre EBIT per shareLaboratorio Reig Jofre Earnings per Share
2026e5.05 undefined0 undefined0.23 undefined
2025e4.72 undefined0 undefined0.2 undefined
2024e4.38 undefined0 undefined0.17 undefined
20234.01 undefined0.16 undefined0.12 undefined
20223.44 undefined0.12 undefined0.1 undefined
20212.99 undefined0.12 undefined0.06 undefined
20202.9 undefined0.12 undefined0.07 undefined
20192.72 undefined0.09 undefined0.07 undefined
20182.6 undefined0.13 undefined0.13 undefined
20172.51 undefined0.13 undefined0.13 undefined
20162.38 undefined0.14 undefined0.11 undefined
20152.35 undefined0.18 undefined0.13 undefined
20140.5 undefined0.04 undefined0.03 undefined
20131.81 undefined0.23 undefined0.14 undefined
20121.79 undefined0.11 undefined0.06 undefined
20111.73 undefined0.01 undefined0 undefined
20101.71 undefined-0.31 undefined0.93 undefined
20092.25 undefined-0.45 undefined-1.31 undefined
20087.88 undefined-0.86 undefined-2.61 undefined
20079.46 undefined0.78 undefined0.09 undefined
20069.01 undefined0.77 undefined0.22 undefined
20056.26 undefined0.32 undefined0.3 undefined
20044.33 undefined0.16 undefined0.33 undefined

Laboratorio Reig Jofre business model

Laboratorio Reig Jofre SA is a leading company in the pharmaceutical industry, specializing in the development, manufacturing, and marketing of drugs. The company was founded in 1929 by the Reig Jofre brothers in Barcelona, Spain. It has since become an international company with a wide portfolio of products and a high level of innovation and quality. The business model of Laboratorio Reig Jofre SA is based on implementing research and innovation in the field of pharmacy. The company has its own R&D department, which collaborates closely with major scientific organizations and universities in Spain to understand and apply the latest developments and innovations in the industry. Laboratorio Reig Jofre SA has three main divisions - human pharmaceuticals, veterinary medicine, and chemical products used in various industries such as cosmetics and food. The human pharmaceutical division includes a variety of products, including prescription drugs, over-the-counter products, and generics, with a focus on therapy areas such as oncology, antibiotics, gynecology, and central nervous system disorders. The veterinary medicine division provides a wide range of vaccines and medications for animal health. The third division of chemical products includes various products such as emulsifiers, preservatives, and natural dyes that can be used in different industries. Some of the most well-known products of Laboratorio Reig Jofre SA include the antibiotic Nitrofurantoin, the analgesic Algiasdin, the hormonal preparation Ovusitol, and the vaccine against Bluetongue in animals. The company has also carried out several successful acquisitions to expand its portfolio and strengthen its international presence. The acquisition of Derivados Quimicos SA (Derma SA) introduced Laboratorio Reig Jofre SA to the skincare sector and strengthened its presence in Latin America. The acquisition of Bioiberica SA introduced the company to the field of bioactive molecules and chondroprotectants. Laboratorio Reig Jofre SA is a company that places quality and innovation at the heart of its activities. The company has a strong corporate culture based on respect, transparency, integrity, and commitment. It has also shown a strong commitment to sustainability and social responsibility, with initiatives such as supporting projects to improve the health of women and children in Africa and implementing environmentally friendly practices in production. Overall, Laboratorio Reig Jofre SA is a leading company in the pharmaceutical industry, capable of offering a wide range of products through research, innovation, and quality. With its diverse portfolio of products and its commitment to sustainability and social responsibility, the company is well-equipped to continue playing a leading role in the industry in the future. Laboratorio Reig Jofre is one of the most popular companies on Eulerpool.com.

Laboratorio Reig Jofre SWOT Analysis

Strengths

Laboratorio Reig Jofre SA holds a significant market share within the pharmaceutical industry, providing a solid foundation for growth and sustainability.

The company offers a wide range of pharmaceutical products, spanning various therapeutic areas, catering to different customer needs. This diversification helps mitigate risks and enables revenue growth.

Laboratorio Reig Jofre SA emphasizes continuous investment in research and development, resulting in the development of groundbreaking medicines and advancements in healthcare technology.

Weaknesses

The company heavily relies on a few key products for a significant portion of its revenue, making it vulnerable to the loss of exclusivity or competition in those specific markets.

Laboratorio Reig Jofre SA's operations are primarily concentrated in specific geographic regions, which could expose the company to risks associated with localized economic downturns or regulatory changes.

Opportunities

The company can explore untapped markets in emerging economies, leveraging its expertise to introduce high-quality pharmaceutical products and establish a strong presence in these regions.

The rapid pace of technological advancements presents opportunities for Laboratorio Reig Jofre SA to develop innovative drug delivery systems, enhance production processes, and improve overall efficiency and effectiveness.

Threats

The pharmaceutical industry is highly competitive, with numerous well-established players and new entrants. Increased competition can affect market share, pricing, and profitability for Laboratorio Reig Jofre SA.

Strict regulations and compliance requirements in the pharmaceutical sector create challenges for Laboratorio Reig Jofre SA, including increased costs, delays in product approvals, and legal complexities.

Laboratorio Reig Jofre Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Laboratorio Reig Jofre historical P/E ratio, EBIT multiple, and P/S ratio

Laboratorio Reig Jofre shares outstanding

The number of shares was Laboratorio Reig Jofre in 2023 — This indicates how many shares 78.804 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Laboratorio Reig Jofre earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Laboratorio Reig Jofre's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Laboratorio Reig Jofre’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Laboratorio Reig Jofre's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Laboratorio Reig Jofre stock splits

In Laboratorio Reig Jofre's history, there have been no stock splits.

Laboratorio Reig Jofre dividend history and estimates

In 2023, Laboratorio Reig Jofre paid a dividend amounting to 0.08 EUR. Dividend means that Laboratorio Reig Jofre distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Laboratorio Reig Jofre provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Laboratorio Reig Jofre’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Laboratorio Reig Jofre's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Laboratorio Reig Jofre Dividend History

DateLaboratorio Reig Jofre Dividend
2026e0.07 undefined
2025e0.06 undefined
2024e0.07 undefined
20230.08 undefined
20221 undefined
20210.05 undefined
20200.04 undefined
20190.04 undefined
20180.04 undefined
20170.05 undefined
20130.7 undefined

Laboratorio Reig Jofre dividend payout ratio

In 2023, Laboratorio Reig Jofre had a payout ratio of 364.43%. The payout ratio indicates the percentage of the company's profits that Laboratorio Reig Jofre distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Laboratorio Reig Jofre represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Laboratorio Reig Jofre could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Laboratorio Reig Jofre's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Laboratorio Reig Jofre Payout Ratio History

DateLaboratorio Reig Jofre Payout ratio
2026e477.52 %
2025e600.38 %
2024e467.76 %
2023364.43 %
2022968.95 %
202169.89 %
202054.46 %
201966.28 %
201833.61 %
201734.32 %
2016364.43 %
2015364.43 %
2014364.43 %
2013500.76 %
2012364.43 %
2011364.43 %
2010364.43 %
2009364.43 %
2008364.43 %
2007364.43 %
2006364.43 %
2005364.43 %
2004364.43 %
Unfortunately, there are currently no price targets and forecasts available for Laboratorio Reig Jofre.

Laboratorio Reig Jofre latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2012-0.94 -0.75  (20.79 %)2012 Q2
6/30/2011(0 %)2011 Q2
9/30/2010(0 %)2010 Q3
12/31/20090.19 -0.02  (-109.9 %)2009 Q4
3/31/20080.19 0.21  (8.9 %)2008 Q1
12/31/20070.19 -0.04  (-119.8 %)2007 Q4
1

Laboratorio Reig Jofre shareholders

%
Name
Stocks
Change
Date
9.99680 % Lopez Gandasegui (Juan Ignacio)8,003,412121,93910/5/2023
62.41781 % Reig Jofre Investments, S.L.49,971,555761,36310/5/2023
6.09755 % Ybarra Careaga (Carmen)4,881,68374,37710/5/2023
2.98955 % Quaero Capital S.A.2,393,42461,4572/27/2024
0.23320 % Prisma Global Asset Management, S.G.I.I.C, S.A.186,70208/31/2023
0.22011 % Santander Asset Management176,219176,2199/30/2023
0.13803 % Crédit Suisse Gestión S.G.I.I.C., S.A.110,50621,07412/31/2023
0.11594 % Solventis A.V., S.A.92,820-13,76712/31/2023
0.04808 % Andbank Wealth Management, SGIIC, S.A.U.38,49308/31/2023
0.04808 % WELCOME ASSET MANAGEMENT S.G.I.I.C., S.A38,49308/31/2023
1
2

Laboratorio Reig Jofre Executives and Management Board

Mr. Ignasi Biosca Reig
Laboratorio Reig Jofre Chief Executive Officer, Executive Director (since 2015)
Compensation 650,000
Ms. Isabel Reig Lopez
Laboratorio Reig Jofre Chairman of the Board, Representative of Reig Jofre Investments SL, Proprietary Director (since 2015)
Compensation 70,000
Ms. Maria Luisa Francoli Plaza
Laboratorio Reig Jofre Independent Director
Compensation 69,000
Mr. Ramon Gomis I de Barbara
Laboratorio Reig Jofre Independent Director
Compensation 69,000
Mr. Ramiro Martinez-Pardo del Valle
Laboratorio Reig Jofre Independent Director
Compensation 69,000
1
2
3

Most common questions regarding Laboratorio Reig Jofre

What values and corporate philosophy does Laboratorio Reig Jofre represent?

Laboratorio Reig Jofre SA is a company that prioritizes values and embraces a strong corporate philosophy. With a focus on integrity, innovation, and excellence, Laboratorio Reig Jofre SA aims to bring pharmaceutical solutions that improve patients' lives. They are committed to conducting business ethically and responsibly, ensuring the highest standards of quality and safety in all their products. Laboratorio Reig Jofre SA emphasizes continuous research and development, collaborating with healthcare professionals and strategic partners to deliver cutting-edge pharmaceutical solutions. This dedication to values and a robust corporate philosophy has established Laboratorio Reig Jofre SA as a trusted and respected player in the pharmaceutical industry.

In which countries and regions is Laboratorio Reig Jofre primarily present?

Laboratorio Reig Jofre SA is primarily present in Spain, where it is headquartered.

What significant milestones has the company Laboratorio Reig Jofre achieved?

Laboratorio Reig Jofre SA, a renowned pharmaceutical company, has achieved several significant milestones throughout its history. Notably, the company has made remarkable strides in research and development, leading to the successful launch of numerous innovative drugs and vaccines. Laboratorio Reig Jofre SA has also expanded its global presence through strategic partnerships and acquisitions, positioning itself as a key player in the international pharmaceutical industry. The company's commitment to quality and patient well-being has garnered recognition, with various certifications and awards honoring its excellence. These achievements highlight Laboratorio Reig Jofre SA's dedication to improving healthcare and its continuous pursuit of innovation in the pharmaceutical sector.

What is the history and background of the company Laboratorio Reig Jofre?

Laboratorio Reig Jofre SA is a renowned pharmaceutical company with a rich history and strong background. Established in Spain, the company has been providing innovative healthcare solutions since its inception. With expertise in research, development, and manufacturing, Laboratorio Reig Jofre SA has become a leading player in the pharmaceutical industry. Its commitment to quality, safety, and efficacy has earned it a solid reputation worldwide. Over the years, the company has expanded its product portfolio, offering a wide range of medicines and healthcare products that cater to diverse medical needs. Laboratorio Reig Jofre SA's consistent growth and dedication to advancing healthcare make it an influential and trusted player in the industry.

Who are the main competitors of Laboratorio Reig Jofre in the market?

The main competitors of Laboratorio Reig Jofre SA in the market include pharmaceutical companies such as Laboratorios Farmacéuticos Rovi SA, Almirall SA, and Grifols SA. These companies operate in the same industry and offer similar products and services, competing for market share and customers. With its strong presence and reputation, Laboratorio Reig Jofre SA faces tough competition from these key players in the pharmaceutical market.

In which industries is Laboratorio Reig Jofre primarily active?

Laboratorio Reig Jofre SA is primarily active in the pharmaceutical industry.

What is the business model of Laboratorio Reig Jofre?

Laboratorio Reig Jofre SA is a pharmaceutical company based in Spain. Their business model is focused on the research, development, and production of innovative pharmaceutical products. They specialize in the manufacturing of medicines, particularly in the areas of women's health, neurology, and hospital products. Laboratorio Reig Jofre SA aims to improve patients' quality of life by providing them with high-quality, reliable, and affordable medications. They strive to be an industry leader, constantly adapting to market demands and regulatory requirements. With a commitment to innovation and a customer-centric approach, Laboratorio Reig Jofre SA continues to make significant contributions to the pharmaceutical industry.

What is the P/E ratio of Laboratorio Reig Jofre 2024?

The Laboratorio Reig Jofre P/E ratio is 17.94.

What is the P/S ratio of Laboratorio Reig Jofre 2024?

The Laboratorio Reig Jofre P/S ratio is 0.68.

What is the Quality Investing of Laboratorio Reig Jofre?

The Quality Investing for Laboratorio Reig Jofre is 6/10.

What is the revenue of Laboratorio Reig Jofre 2024?

The expected Laboratorio Reig Jofre revenue is 350.29 M EUR.

How high is the profit of Laboratorio Reig Jofre 2024?

The expected Laboratorio Reig Jofre profit is 13.22 M EUR.

What is the business model of Laboratorio Reig Jofre

Laboratorio Reig Jofre SA (LRJ) is a pharmaceutical company that specializes in the manufacture of medicinal products, vaccines, and over-the-counter products. The company was founded in 1929 and is headquartered in Barcelona, Spain. LRJ is listed on the Madrid stock exchange and employs approximately 1,000 people worldwide.

What is the Laboratorio Reig Jofre dividend?

Laboratorio Reig Jofre pays a dividend of 1 EUR distributed over payouts per year.

How often does Laboratorio Reig Jofre pay dividends?

The dividend cannot currently be calculated for Laboratorio Reig Jofre or the company does not pay out a dividend.

What is the Laboratorio Reig Jofre ISIN?

The ISIN of Laboratorio Reig Jofre is ES0165359029.

What is the Laboratorio Reig Jofre WKN?

The WKN of Laboratorio Reig Jofre is A140EW.

What is the Laboratorio Reig Jofre ticker?

The ticker of Laboratorio Reig Jofre is RJF.MC.

How much dividend does Laboratorio Reig Jofre pay?

Over the past 12 months, Laboratorio Reig Jofre paid a dividend of 0.08 EUR . This corresponds to a dividend yield of about 2.66 %. For the coming 12 months, Laboratorio Reig Jofre is expected to pay a dividend of 0.06 EUR.

What is the dividend yield of Laboratorio Reig Jofre?

The current dividend yield of Laboratorio Reig Jofre is 2.66 %.

When does Laboratorio Reig Jofre pay dividends?

Laboratorio Reig Jofre pays a quarterly dividend. This is distributed in the months of July, August, June, June.

How secure is the dividend of Laboratorio Reig Jofre?

Laboratorio Reig Jofre paid dividends every year for the past 10 years.

What is the dividend of Laboratorio Reig Jofre?

For the upcoming 12 months, dividends amounting to 0.06 EUR are expected. This corresponds to a dividend yield of 2.1 %.

In which sector is Laboratorio Reig Jofre located?

Laboratorio Reig Jofre is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratorio Reig Jofre kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratorio Reig Jofre from 6/21/2024 amounting to 0.04 EUR, you needed to have the stock in your portfolio before the ex-date on 5/17/2024.

When did Laboratorio Reig Jofre pay the last dividend?

The last dividend was paid out on 6/21/2024.

What was the dividend of Laboratorio Reig Jofre in the year 2023?

In the year 2023, Laboratorio Reig Jofre distributed 0.996 EUR as dividends.

In which currency does Laboratorio Reig Jofre pay out the dividend?

The dividends of Laboratorio Reig Jofre are distributed in EUR.

All fundamentals about Laboratorio Reig Jofre

Our stock analysis for Laboratorio Reig Jofre Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorio Reig Jofre Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.